Medical Pharmacology Question Bank

Chapter 1: General Pharmacology — Module 5: Drug Development and Regulation
Tier: Tier 1 — Foundational Recall

1. Which of the following best defines the CYP2D6 ultrarapid metabolizer (UM) phenotype and its clinical consequence for a patient prescribed codeine?

A) The UM phenotype results from complete loss of both CYP2D6 alleles, producing no functional enzyme; codeine cannot be converted to morphine, resulting in analgesic failure
B) The UM phenotype results from CYP2D6 gene duplication or multiplication, producing markedly elevated enzyme activity; codeine is rapidly and extensively O-demethylated to morphine, generating supratherapeutic morphine concentrations and risking respiratory depression, sedation, and death — particularly dangerous in nursing infants of UM mothers receiving codeine postpartum
C) The UM phenotype results from a single gain-of-function SNP in the CYP2D6 promoter, producing mildly increased enzyme activity; codeine is converted to morphine at a rate approximately 20% above the extensive metabolizer baseline, producing marginally enhanced analgesia with no safety concerns
D) The UM phenotype is defined by a CYP2D6 activity score of 0.0, reflecting complete enzyme absence; patients with this phenotype require higher codeine doses to achieve equivalent analgesia compared to extensive metabolizers
E) The UM phenotype results from CYP2D6 inhibition by a concurrently administered drug, reducing codeine conversion to morphine and causing analgesic failure in an otherwise extensive metabolizer patient

ANSWER: B

Rationale:

The CYP2D6 ultrarapid metabolizer phenotype results from copy number variation — typically duplication (CYP2D6*1×2) or multiplication (CYP2D6*2×N, up to 13 copies reported) of functional CYP2D6 alleles, producing markedly supranormal enzyme activity. Codeine (3-methylmorphine) is a prodrug that requires CYP2D6-mediated O-demethylation to morphine for its analgesic and respiratory depressant effects — approximately 10% of a codeine dose is converted to morphine in extensive metabolizers (EM). In UM individuals, this conversion is dramatically accelerated and more complete: morphine is generated rapidly and in quantities that can produce life-threatening opioid toxicity at standard codeine doses. This pharmacogenomic safety issue reached tragic clinical prominence through cases of infant deaths: nursing mothers who were CYP2D6 UMs received codeine for postpartum analgesia, converted it rapidly to morphine, and transferred supratherapeutic morphine concentrations to their infants through breast milk — causing neonatal respiratory depression and death. These cases led the FDA and EMA to issue contraindications for codeine use in breastfeeding mothers and in children under 12. The UM phenotype is most prevalent in populations of North African, Ethiopian, and Saudi Arabian ancestry (up to 29% prevalence) and is also present in approximately 1–2% of Northern Europeans. Option A describes the poor metabolizer (PM) phenotype. Option C understates the magnitude of UM enzyme activity and the severity of the safety concern — UM conversion to morphine is not marginally elevated but dramatically amplified. Option D incorrectly assigns an activity score of 0.0 to UMs — an activity score of 0.0 defines PMs; UMs have activity scores >2.0. Option E describes a phenoconversion scenario (drug-induced metabolizer status change), not a genetically determined UM phenotype.

2. The FDA has issued a boxed warning for clopidogrel regarding CYP2C19 poor metabolizer status. Which of the following best explains the pharmacogenomic basis of this warning?

A) CYP2C19 poor metabolizers have increased clopidogrel plasma concentrations due to reduced hepatic first-pass metabolism, producing supratherapeutic antiplatelet effects and increased bleeding risk compared to normal metabolizers
B) Clopidogrel is an inactive prodrug requiring CYP2C19-mediated hepatic bioactivation to its active thiol metabolite; CYP2C19 poor metabolizers (carrying two loss-of-function alleles, most commonly CYP2C19*2 and *3) cannot adequately generate the active metabolite, resulting in reduced platelet P2Y12 receptor inhibition, inadequate antiplatelet effect, and increased risk of major adverse cardiovascular events including stent thrombosis
C) CYP2C19 poor metabolizers convert clopidogrel to a toxic hepatotoxic metabolite rather than the active thiol metabolite, producing drug-induced liver injury at standard doses — the FDA warning addresses hepatotoxicity rather than cardiovascular efficacy
D) The FDA boxed warning applies to CYP2C19 ultrarapid metabolizers who over-activate clopidogrel, producing platelet destruction and severe thrombocytopenia that mimics HIT
E) CYP2C19 poor metabolizer status reduces clopidogrel absorption from the gastrointestinal tract through impaired intestinal CYP2C19-mediated transport, producing reduced bioavailability rather than impaired hepatic bioactivation

ANSWER: B

Rationale:

Clopidogrel is a thienopyridine prodrug that requires two sequential hepatic oxidation steps for bioactivation. The first step is mediated primarily by CYP2C19 (with contributions from CYP1A2 and CYP2B6), generating a thiolactone intermediate; the second step generates the active thiol metabolite that irreversibly blocks the platelet ADP P2Y12 receptor, inhibiting ADP-induced platelet aggregation. CYP2C19 loss-of-function alleles — principally CYP2C19*2 (an intronic splice variant present in approximately 15% of Europeans, 30% of Asians) and CYP2C19*3 (prevalent in Asian populations) — dramatically reduce bioactivation efficiency. Patients homozygous for loss-of-function alleles (poor metabolizers, approximately 2–5% of Europeans, 15–25% of Asians) generate substantially reduced active metabolite concentrations — ex vivo platelet aggregation studies confirm significantly less P2Y12 receptor inhibition. The critical clinical consequence is inadequate antiplatelet protection: multiple large clinical trials and meta-analyses demonstrate that CYP2C19 PM patients receiving clopidogrel after acute coronary syndrome or coronary stent implantation have significantly higher rates of major adverse cardiovascular events and stent thrombosis compared to normal (extensive) metabolizers. The FDA issued a boxed warning in 2010 requiring clopidogrel labeling to state that poor metabolizers may not receive the full benefit of clopidogrel and that genotyping should be considered — alternative antiplatelet agents (prasugrel, ticagrelor) that do not require CYP2C19 bioactivation are recommended in confirmed PMs. Option A is incorrect — clopidogrel is a prodrug; reduced CYP2C19 activity reduces, not increases, active metabolite generation and produces underdosing, not supratherapeutic effects. Option C is incorrect — CYP2C19 PM status produces inadequate bioactivation, not generation of a hepatotoxic metabolite. Option D is incorrect — UM status (CYP2C19*17 gain-of-function allele, present in approximately 20–30% of Northern Europeans) produces enhanced bioactivation and potent ially greater platelet inhibition, but does not cause thrombocytopenia or a HIT-like syndrome. Option E is incorrect — clopidogrel bioactivation occurs primarily in the liver, not through intestinal CYP2C19-mediated transport.

3. A patient prescribed warfarin carries the CYP2C9*2/*3 genotype and the VKORC1 -1639G>A (AA) variant. Which of the following best predicts the combined pharmacogenomic impact on warfarin dosing?

A) CYP2C9*2/*3 produces increased S-warfarin clearance, requiring higher warfarin doses; the VKORC1 AA variant increases VKORC1 enzyme activity, further increasing warfarin dose requirements — the combined genotype predicts a high warfarin dose requirement of >7 mg/day
B) CYP2C9*2/*3 produces reduced S-warfarin clearance (impaired CYP2C9-mediated hydroxylation), increasing warfarin plasma concentrations; the VKORC1 -1639G>A AA variant reduces VKORC1 expression, increasing target sensitivity to warfarin's inhibitory effect — the combined genotype predicts markedly reduced warfarin dose requirements, typically 1–3 mg/day, with substantially elevated bleeding risk at standard doses
C) CYP2C9*2/*3 reduces warfarin absorption from the gastrointestinal tract, requiring higher doses to achieve therapeutic plasma concentrations; the VKORC1 AA variant has no effect on warfarin pharmacodynamics in patients with this CYP2C9 genotype
D) The CYP2C9*2/*3 genotype predicts ultrarapid metabolism of S-warfarin; the VKORC1 AA variant encodes a warfarin-resistant VKORC1 enzyme — the combined effect is complete warfarin resistance requiring alternative anticoagulation
E) VKORC1 and CYP2C9 genotypes influence only R-warfarin pharmacology; since S-warfarin is the pharmacologically active enantiomer metabolized exclusively by CYP3A4, these genetic variants have no meaningful impact on anticoagulant dose requirements

ANSWER: B

Rationale:

This question integrates pharmacogenomic effects at two independent levels of warfarin pharmacology — pharmacokinetics (CYP2C9 metabolism) and pharmacodynamics (VKORC1 target sensitivity) — to predict combined dose implications. CYP2C9*2 and CYP2C9*3 are loss-of-function alleles that reduce S-warfarin hydroxylase activity by approximately 30% and 90%, respectively, compared to wild-type CYP2C9*1. A CYP2C9*2/*3 compound heterozygote has severely impaired S-warfarin clearance, producing elevated and prolonged S-warfarin plasma concentrations at any given dose. S-warfarin is the pharmacologically dominant enantiomer (approximately 3–5× more potent anticoagulant than R-warfarin) and is metabolized almost exclusively by CYP2C9. VKORC1 -1639G>A is a promoter SNP in which the A allele reduces VKORC1 gene transcription, producing less VKORC1 enzyme protein (vitamin K epoxide reductase complex 1). Less VKORC1 protein means the same warfarin plasma concentration inhibits a greater proportion of the total enzyme pool — the pharmacodynamic sensitivity to warfarin is increased. The VKORC1 AA homozygous genotype is the most warfarin-sensitive pharmacodynamic genotype. Combined, CYP2C9*2/*3 (increased warfarin exposure through impaired metabolism) and VKORC1 AA (increased pharmacodynamic sensitivity) create a double pharmacogenomic vulnerability: these patients require dramatically reduced warfarin doses — typically 1–3 mg/day or less — to achieve therapeutic INR. Standard loading doses (5–10 mg) in such patients produce severe supratherapeutic INR elevations and major bleeding risk. This pharmacogenomic profile is incorporated into FDA-approved warfarin dosing algorithms (the Gage and IWPC algorithms) that adjust initial warfarin dose based on CYP2C9 and VKORC1 genotype. Option A reverses both pharmacogenomic effects incorrectly. Option C incorrectly attributes the CYP2C9 effect to absorption rather than metabolism. Option D is incorrect — CYP2C9*2 and *3 are loss-of-function (reduced activity) alleles, not gain-of-function (ultrarapid) alleles; VKORC1 AA increases, not reduces, warfarin sensitivity. Option E is incorrect — CYP2C9 is the primary enzyme metabolizing S-warfarin (not CYP3A4), and CYP2C9/VKORC1 genotypes are among the strongest pharmacogenomic predictors of warfarin dose requirements.

4. SLCO1B1 encodes the organic anion transporting polypeptide 1B1 (OATP1B1), a hepatic uptake transporter. The SLCO1B1 c.521T>C (rs4149056) variant is associated with statin-induced myopathy. Which of the following best explains this association?

A) The SLCO1B1 c.521T>C variant increases OATP1B1 transporter activity, enhancing hepatic uptake of statins and reducing systemic statin plasma concentrations — patients with this variant require higher statin doses to achieve equivalent LDL lowering
B) The SLCO1B1 c.521T>C variant reduces OATP1B1 transporter activity, impairing hepatic uptake of statins (particularly simvastatin acid); statins accumulate in the systemic circulation at higher concentrations than intended, increasing their exposure to skeletal muscle — the primary site of statin myotoxicity — raising the risk of myalgia, myopathy, and potentially rhabdomyolysis
C) The SLCO1B1 c.521T>C variant alters statin pharmacodynamics at the HMG-CoA reductase active site, reducing statin inhibitory potency and requiring dose escalation that indirectly causes myopathy through off-target effects
D) The SLCO1B1 c.521T>C variant impairs renal tubular secretion of statin metabolites, causing their accumulation and conversion back to parent drug in the systemic circulation — myopathy results from the increased circulating metabolite rather than from the parent statin
E) The SLCO1B1 variant affects only pravastatin pharmacokinetics; other statins (simvastatin, atorvastatin, rosuvastatin) are not transported by OATP1B1 and are unaffected by this genetic variant

ANSWER: B

Rationale:

OATP1B1 is a sodium-independent organic anion transporting polypeptide expressed on the sinusoidal (basolateral) membrane of hepatocytes, mediating the uptake of multiple drugs from portal blood into liver cells. For statins, hepatic OATP1B1-mediated uptake is the rate-limiting step for delivering the drug to its pharmacological target (HMG-CoA reductase in hepatocytes) and for hepatic elimination. The SLCO1B1 c.521T>C variant (encoding the Val174Ala amino acid substitution in OATP1B1) reduces transporter activity through impaired membrane localization — the OATP1B1 174Ala protein is retained intracellularly rather than trafficking efficiently to the hepatocyte sinusoidal membrane, reducing functional transporter surface expression. Reduced OATP1B1 activity decreases hepatic statin uptake: statins that would normally be extracted by the liver remain in the systemic circulation at higher concentrations. For simvastatin acid (the active form of simvastatin after prodrug hydrolysis), the SLCO1B1 c.521T>C variant produces the most dramatic effect — a genome-wide association study (GWAS) published in the New England Journal of Medicine (SEARCH Collaborative Group, 2008) demonstrated that each copy of the C allele approximately doubled the odds of myopathy, and CC homozygotes had approximately 16-fold increased myopathy risk with simvastatin 80 mg compared to TT homozygotes. The mechanism is pharmacokinetic: increased systemic simvastatin acid exposure greater drug delivery to skeletal muscle enhanced mitochondrial CoQ10 depletion, impaired cholesterol synthesis in muscle cell membranes, and mevalonate pathway disruption myocyte toxicity. Clinical guideline implications: CPIC guidelines recommend reduced simvastatin doses or alternative statins (rosuvastatin, pravastatin — less affected by OATP1B1 variation) in CC homozygotes. Option A is incorrect — the c.521T>C variant reduces, not increases, OATP1B1 activity; reduced hepatic uptake increases systemic drug exposure. Option C is incorrect — SLCO1B1 variation is a pharmacokinetic transporter effecstatin substrate, OATP1B1 transports multiple statins including atorvastatin, rosuvastatin, and pravastatin acid; the degree of effect varies by statin but is not exclusive to pravastatin.t, not a pharmacodynamic effect at HMG-CoA reductase. Option D is incorrect — OATP1B1 mediates hepatic uptake, not renal tubular secretion; the mechanism is systemic statin accumulation from impaired hepatic extraction, not metabolite recycling. Option E is incorrect — while simvastatin acid is the most studied and most affected.

5. HLA-B*5701 genotyping is required before initiating abacavir therapy. Which of the following best explains the pharmacogenomic basis of this requirement?

A) HLA-B*5701 encodes a variant HLA molecule that directly binds abacavir in the peptide-binding groove, presenting the drug as a neoantigen to CD8+ cytotoxic T lymphocytes — this leads to a Type IV delayed hypersensitivity reaction (abacavir hypersensitivity syndrome) characterized by fever, rash, gastrointestinal symptoms, and respiratory symptoms, which is potentially fatal upon rechallenge; HLA-B*5701 screening and exclusion of carriers from abacavir therapy has virtually eliminated abacavir hypersensitivity syndrome
B) HLA-B*5701 encodes a variant of CYP3A4 that metabolizes abacavir to a reactive quinone metabolite causing direct hepatotoxic injury — genotyping identifies patients at risk of severe hepatotoxicity, not hypersensitivity
C) HLA-B*5701 reduces abacavir renal clearance by impairing OAT3-mediated tubular secretion, causing abacavir accumulation and dose-dependent nephrotoxicity in positive carriers — genotyping identifies patients requiring dose reduction
D) HLA-B*5701 is a pharmacokinetic variant that reduces abacavir oral bioavailability through enhanced intestinal P-glycoprotein efflux — positive carriers require higher abacavir doses to achieve therapeutic plasma concentrations for HIV suppression
E) HLA-B*5701 produces a gain-of-function variant of thymidine kinase that phosphorylates abacavir more rapidly than wild-type enzyme, generating toxic triphosphate concentrations that cause mitochondrial DNA depletion and lactic acidosis

ANSWER: A

Rationale:

Abacavir hypersensitivity syndrome (AHS) is a landmark example of HLA-associated drug hypersensitivity — the paradigmatic case that established the clinical utility of prospective pharmacogenomic screening to prevent severe immune-mediated adverse drug reactions. Abacavir (a nucleoside reverse transcriptase inhibitor, NRTI) non-covalently but with high affinity binds directly within the peptide-binding groove of the HLA-B*5701 molecule. This binding fundamentally alters the repertoire of endogenous peptides that HLA-B*5701 can present — abacavir acts as a chemical wedge that changes the shape and electrostatic properties of the groove, causing it to preferentially bind and present a new set of self-peptides that would not normally be presented. These abacavir-modified HLA-B*5701/peptide complexes are recognized as neoantigens by naive CD8+ cytotoxic T lymphocytes, which become activated and clonally expand during initial abacavir exposure (sensitization). Upon re-exposure, these primed CD8+ T cells mount a rapid, robust Type IV (T cell-mediated) hypersensitivity response — producing the abacavir hypersensitivity syndrome: fever, rash, gastrointestinal symptoms (nausea, vomiting, diarrhea), and in severe cases respiratory compromise, hypotension, and death (reported fatalities with rechallenge). The PREDICT-1 trial (Phillips et al., NEJM 2008) demonstrated that prospective HLA-B*5701 screening followed by exclusion of positive carriers from abacavir therapy reduced immunologically confirmed hypersensitivity from approximately 2.7% to 0% — effectively eliminating the syndrome through pharmacogenomic screening. HLA-B*5701 is now standard of care prior to abacavir initiation in all international HIV treatment guidelines. Option B is incorrect — HLA-B*5701 is an immunogenetics variant, not a CYP3A4 variant; abacavir is not metabolized by CYP3A4 to a reactive quinone. Option C is incorrect — HLA-B*5701 mediates immune hypersensitivity, not renal transporter function or nephrotoxicity. Option D is incorrect — HLA-B*5701 has no pharmacokinetic function; it is an antigen-presenting molecule, not a drug transporter or efflux pump.

6. Option E is incorrect — abacavir's antiretroviral activity requires intracellular phosphorylation by cellular kinases to its triphosphate form, but HLA-B*5701 plays no role in this activation pathway; mitochondrial toxicity from abacavir triphosphate is not the HLA-B*5701-associated mechanism. TPMT (thiopurine S-methyltransferase) and NUDT15 are two genes whose variant genotypes predict thiopurine toxicity. Which of the following best summarizes their pharmacogenomic roles?

A) TPMT variants increase thiopurine conversion to 6-thioguanine nucleotides (6-TGNs) in red blood cells and bone marrow; NUDT15 variants reduce 6-TGN degradation — both independently cause 6-TGN accumulation and life-threatening myelosuppression; poor metabolizer genotypes at either locus predict severe, potentially fatal bone marrow suppression at standard thiopurine doses
B) TPMT and NUDT15 variants both reduce thiopurine activation to 6-TGNs, producing therapeutic failure rather than toxicity — genotyping identifies patients requiring dose escalation to achieve immunosuppressive efficacy
C) TPMT variants cause hepatotoxicity from thiopurine accumulation in hepatocytes, while NUDT15 variants cause nephrotoxicity from 6-TGN accumulation in renal tubular cells — the two genes predict distinct organ toxicities requiring different dose adjustments
D) TPMT encodes an enzyme that activates thiopurines to 6-TGNs in the liver; loss-of-function TPMT variants reduce hepatic activation, reducing systemic 6-TGN exposure and requiring dose increases — NUDT15 is a renal elimination transporter whose variants reduce 6-TGN renal excretion, causing myelosuppression from accumulated 6-TGNs in marrow cells
E) TPMT and NUDT15 variants are clinically relevant only in pediatric ALL treatment protocols; adult patients receiving azathioprine or 6-mercaptopurine for inflammatory bowel disease or rheumatoid arthritis are not at risk for thiopurine myelosuppression regardless of genotype

ANSWER: A

Rationale:

Thiopurine pharmacogenomics illustrates how multiple independent genetic variants in different metabolic pathways can converge on the same catastrophic toxicity — severe myelosuppression — through mechanistically distinct routes. Thiopurines (azathioprine, 6-mercaptopurine, 6-thioguanine) are converted to 6-thioguanine nucleotides (6-TGNs) through a multi-step pathway. 6-TGNs incorporate into DNA and RNA of rapidly dividing cells, disrupting nucleic acid synthesis and causing cell death — this is both the therapeutic mechanism (targeting rapidly dividing leukemia cells or activated lymphocytes) and the toxicity mechanism (targeting bone marrow progenitors). TPMT (thiopurine S-methyltransferase) is an inactivating enzyme that S-methylates thiopurines and their metabolites, diverting them away from the 6-TGN pathway. TPMT loss-of-function variants (TPMT*2, *3A, *3C — present in approximately 10% of Europeans as heterozygotes, approximately 0.3% as homozygotes) reduce thiopurine inactivation, shunting more substrate toward 6-TGN generation and causing 6-TGN accumulation in red blood cells and bone marrow. NUDT15 (nudix hydrolase 15) encodes a phosphohydrolase that degrades thiopurine nucleotide metabolites (specifically 6-thio-GTP). NUDT15 loss-of-function variants (most importantly NUDT15*2, *3) reduce 6-TGN degradation, allowing 6-TGNs to accumulate to toxic concentrations in hematopoietic cells. NUDT15 variants are particularly prevalent in East Asian, South Asian, and Hispanic populations (where TPMT variants are less common) — explaining why Asian patients historically experienced higher rates of severe thiopurine toxicity at doses tolerated by European patients. CPIC guidelines recommend genotyping both TPMT and NUDT15 before initiating thiopurines, with 50–90% dose reductions for intermediate or poor metabolizer phenotypes. Option B is incorrect — both TPMT and NUDT15 loss-of-function variants cause 6-TGN accumulation and toxicity, not therapeutic failure; they increase, not decrease, 6-TGN exposure. Option C is incorrect — both genes primarily predict myelosuppression risk, not distinct hepatic and renal organ toxicities. Option D is incorrect — TPMT is an inactivating (not activating) enzyme; loss-of-function increases 6-TGN exposure; NUDT15 is not a renal elimination transporter. Option E is incorrect — TPMT and NUDT15 pharmacogenomics apply to all patients receiving thiopurines regardless of age or indication; adult patients on azathioprine for IBD or autoimmune disease are at equivalent myelosuppression risk with loss-of-function genotypes.

7. The Clinical Pharmacogenomics Implementation Consortium (CPIC) framework provides actionable pharmacogenomic guidance. Which of the following best describes the CPIC classification system and its clinical utility?

A) CPIC classifies drugs into A, B, C, and D categories based on their chemical structure and mechanism of action — drugs in category A are pharmacogenomically relevant and require genotyping before use in all patients worldwide
B) CPIC is a regulatory agency that approves pharmacogenomic biomarkers for inclusion in drug prescribing information — CPIC approval is required before a pharmacogenomic test can be used clinically in the United States
C) CPIC provides peer-reviewed, evidence-based clinical practice guidelines that translate pharmacogenomic test results into specific prescribing recommendations — guidelines are stratified by evidence level (A–D) reflecting the strength of gene-drug interaction evidence, with Level A representing the strongest evidence requiring action; CPIC does not mandate genotyping but provides guidance on how to act when genotype results are available
D) reflecting the strength of gene-drug interaction evidence, with Level A representing the strongest evidence requiring action; CPIC does not mandate genotyping but provides guidance on how to act when genotype results are available D. CPIC classifies patients into phenotype categories (ultrarapid, extensive, intermediate, poor metabolizer) based solely on self-reported ancestry — genotyping is not required for CPIC-based prescribing decisions
E) CPIC guidelines apply exclusively to CYP enzyme polymorphisms — HLA, transporter, and pharmacodynamic target gene variants (VKORC1, SLCO1B1, TPMT, NUDT15) are outside CPIC's scope and are addressed by separate regulatory frameworks

ANSWER: C

Rationale:

The Clinical Pharmacogenomics Implementation Consortium (CPIC) was established in 2009 as a shared project between PharmGKB and the Pharmacogenomics Research Network, with the explicit goal of addressing a key barrier to clinical implementation of pharmacogenomics: even when pharmacogenomic test results are available, clinicians frequently do not know how to translate them into prescribing decisions. CPIC guidelines address this gap by providing peer-reviewed, freely available, evidence-based clinical practice guidelines that translate specific genotype results into actionable prescribing recommendations. Key features of the CPIC framework: (1) Evidence classification — drug-gene pairs are assigned clinical pharmacogenomics levels (A = strong evidence for gene-drug interaction with clinical relevance; B = moderate evidence; C = weak/limited evidence; D = reputed interaction not substantiated by strong evidence). (2) Prescribing recommendations — for each genotype/phenotype category (UM, EM, IM, PM), CPIC provides specific prescribing recommendations: "use as directed," "consider alternative agent," "use with dose reduction," "contraindicated," etc. (3) CPIC does not mandate genotyping or require it to be performed before every prescription — it is designed for the situation where genotype results are already available (e.g., from a previously performed pharmacogenomic panel) and the clinician needs guidance on how to apply them. CPIC covers CYP enzymes, HLA alleles, transporter genes (SLCO1B1), pharmacodynamic targets (VKORC1), and pathway enzymes (TPMT, NUDT15, G6PD, DPYD) — a comprehensive scope. Option A is incorrect — CPIC does not classify drugs by chemical structure; its classification system relates to the strength of pharmacogenomic evidence for gene-drug interactions. Option B is incorrect — CPIC is not a regulatory agency; it does not approve biomarkers for regulatory use; it is an academic consortium providing clinical implementation guidelines. Option D is incorrect — CPIC phenotype predictions require genotyping results; self-reported ancestry is an imprecise proxy and not the basis of CPIC recommendations. Option E is incorrect — CPIC guidelines explicitly cover HLA alleles (abacavir/HLA-B*5701, carbamazepine/HLA-B*1502, allopurinol/HLA-B*5801), transporter genes (SLCO1B1/statins), and pharmacodynamic targets (VKORC1/warfarin) — the scope extends well beyond CYP enzymes.

8. HLA-B*5801 is a pharmacogenomic biomarker with specific clinical relevance to which of the following drug-reaction associations?

A) HLA-B*5801 is associated with carbamazepine-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in Han Chinese and Southeast Asian populations — genotyping before carbamazepine initiation is mandated by the FDA for patients of Asian ancestry
B) HLA-B*5801 is associated with allopurinol-induced severe cutaneous adverse reactions (SCAR), specifically SJS and TEN — the risk is highest in Han Chinese, Thai, and Korean populations where the allele is more prevalent; CPIC and Asian regulatory agencies recommend genotyping before allopurinol initiation in high-risk populations
C) HLA-B*5801 is associated with abacavir hypersensitivity syndrome — carriers of this allele develop a potentially fatal multi-organ delayed hypersensitivity reaction upon exposure to abacavir
D) HLA-B*5801 is associated with flucloxacillin-induced cholestatic hepatitis — the allele encodes a bile salt export pump variant that accumulates flucloxacillin metabolites in hepatocytes, causing direct hepatotoxic injury
E) HLA-B*5801 is associated with statin-induced severe myopathy through immune-mediated necrotizing myopathy — the allele encodes a muscle-specific protein that forms the neoantigen targeted by statin-induced autoantibodies against HMG-CoA reductase

ANSWER: B

Rationale:

The HLA pharmacogenomics landscape involves multiple distinct drug-HLA allele associations, each specific to a particular drug and adverse reaction type — requiring precise knowledge of which allele predicts which drug reaction. HLA-B*5801 is strongly and specifically associated with allopurinol-induced severe cutaneous adverse reactions (SCAR) — specifically Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), the most severe end of the drug hypersensitivity spectrum with mortality rates of 10–30% for SJS and up to 50% for TEN. The association was first identified in Han Chinese patients (Hung et al., PNAS 2005) and subsequently confirmed in Thai, Korean, and other Asian populations. HLA-B*5801 prevalence is approximately 6–8% in Han Chinese, approximately 8% in Thai populations, and less than 1% in European populations — explaining the substantially higher incidence of allopurinol-SCAR in Asian countries. The mechanistic basis parallels abacavir-HLA-B*5701: allopurinol or its active metabolite oxypurinol likely occupies the HLA-B*5801 peptide-binding groove, altering the presented peptide repertoire and triggering CD8+ T cell-mediated keratinocyte destruction. CPIC (Level A evidence) and multiple Asian regulatory agencies (Taiwan, Thailand, Korea, Singapore) recommend or mandate HLA-B*5801 genotyping before allopurinol initiation in at-risk Asian populations — Taiwan has implemented nationwide HLA-B*5801 screening before allopurinol prescribing. Option A describes the HLA-B*1502 carbamazepine association — HLA-B*1502 (not HLA-B*5801) is associated with carbamazepine-induced SJS/TEN in Han Chinese and Southeast Asian populations; these are different HLA alleles with different drug specificities. Option C describes the abacavir association — this is HLA-B*5701, not HLA-B*5801; these are critically distinct alleles. Option D is incorrect — HLA-B*7601 (not HLA-B*5801) has been associated with flucloxacillin hepatotoxicity, and the mechanism is different from SCAR. Option E is incorrect — immune-mediated necrotizing myopathy (IMNM) associated with statins involves anti-HMG-CoA reductase antibodies, but this is not an HLA-B*5801 association; the specific HLA associations with statin IMNM are different alleles in different populations.